Intranasal COVID-19 vaccine shows promise in reducing severe symptoms

The race for RSV vac­cine mar­ket dom­i­nance con­tin­ues with Pfiz­er re­port­ing on Tues­day that Abrys­vo passed its reg­is­tra­tional test in at-risk peo­ple aged 18 to

Af­ter 17 years of back and forth with cit­i­zen pe­ti­tions and two ad­vi­so­ry com­mit­tees, the FDA on Thurs­day pro­posed to pull com­mon­ly-used nasal de­con­ges­tant ac­tive

Hicks is an associate professor of surgery and a director of clinical outcomes research. The recent New York Times article highlighting inappropriate treatment patterns among